A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotheapeutic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
|Effective start/end date||5/2/08 → 5/31/13|
- Argos Therapeutics, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.